Veru Inc. (VERU): Price and Financial Metrics


Veru Inc. (VERU): $8.09

-0.11 (-1.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VERU POWR Grades


  • VERU scores best on the Sentiment dimension, with a Sentiment rank ahead of 93.82% of US stocks.
  • The strongest trend for VERU is in Stability, which has been heading down over the past 52 weeks.
  • VERU ranks lowest in Stability; there it ranks in the 11th percentile.

VERU Stock Summary

  • With a one year PEG ratio of 3,995.93, Veru Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.05% of US stocks.
  • The ratio of debt to operating expenses for Veru Inc is higher than it is for about merely 9.5% of US stocks.
  • With a year-over-year growth in debt of -72.88%, Veru Inc's debt growth rate surpasses just 4.62% of about US stocks.
  • Stocks that are quantitatively similar to VERU, based on their financial statements, market capitalization, and price volatility, are AVAV, NVCR, EVOP, VRRM, and WDAY.
  • VERU's SEC filings can be seen here. And to visit Veru Inc's official web site, go to www.verupharma.com.

VERU Valuation Summary

  • VERU's price/sales ratio is 12.4; this is 226.32% higher than that of the median Healthcare stock.
  • Over the past 243 months, VERU's price/earnings ratio has gone down 4941.2.
  • Over the past 243 months, VERU's price/sales ratio has gone up 11.2.

Below are key valuation metrics over time for VERU.

Stock Date P/S P/B P/E EV/EBIT
VERU 2021-08-31 12.4 4.6 -4946.5 697.3
VERU 2021-08-30 12.1 4.5 -4824.3 676.5
VERU 2021-08-27 12.7 4.7 -5041.0 713.3
VERU 2021-08-26 11.1 4.1 -4425.0 608.7
VERU 2021-08-25 11.3 4.2 -4486.1 619.1
VERU 2021-08-24 11.2 4.1 -4463.9 615.3

VERU Growth Metrics

  • Its 5 year cash and equivalents growth rate is now at -30.34%.
  • Its 5 year price growth rate is now at 198.5%.
  • Its year over year cash and equivalents growth rate is now at 5244.06%.
Over the past 33 months, VERU's revenue has gone up $41,497,771.

The table below shows VERU's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 57.36225 -15.10567 -0.143691
2021-03-31 50.02842 1.067131 -0.476205
2020-12-31 46.63103 1.239648 1.559267
2020-09-30 42.59206 -1.930095 -18.97353
2020-06-30 39.57128 -2.543986 -10.20145
2020-03-31 38.97658 -6.410119 -9.950143

VERU's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VERU has a Quality Grade of C, ranking ahead of 61.3% of graded US stocks.
  • VERU's asset turnover comes in at 0.473 -- ranking 97th of 681 Pharmaceutical Products stocks.
  • NBIX, MNKD, and REPH are the stocks whose asset turnover ratios are most correlated with VERU.

The table below shows VERU's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.473 0.788 0.038
2021-03-31 0.540 0.756 0.193
2020-12-31 0.760 0.737 0.295
2020-09-30 0.750 0.723 -0.912
2020-06-30 0.691 0.684 -0.376
2020-03-31 0.716 0.696 -0.365

VERU Price Target

For more insight on analysts targets of VERU, see our VERU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.40 Average Broker Recommendation 1.3 (Strong Buy)

VERU Stock Price Chart Interactive Chart >

Price chart for VERU

VERU Price/Volume Stats

Current price $8.09 52-week high $24.57
Prev. close $8.20 52-week low $2.30
Day low $8.04 Volume 341,000
Day high $8.29 Avg. volume 1,993,198
50-day MA $8.59 Dividend yield N/A
200-day MA $9.63 Market Cap 646.02M

Veru Inc. (VERU) Company Bio


Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is based in Miami, Florida.


VERU Latest News Stream


Event/Time News Detail
Loading, please wait...

VERU Latest Social Stream


Loading social stream, please wait...

View Full VERU Social Stream

Latest VERU News From Around the Web

Below are the latest news stories about Veru Inc that investors may wish to consider to help them evaluate VERU as an investment opportunity.

Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer

-- Enobosarm is a novel targeted hormone drug to be evaluated in the 3 rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed, validated, and used to select patients who are most likely to respond to enobosarm treatment --

Intrado Digital Media | October 13, 2021

7 Top-Rated Pharmaceutical Stocks To Invest in for October

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | October 4, 2021

What Is The Ownership Structure Like For Veru Inc. (NASDAQ:VERU)?

If you want to know who really controls Veru Inc. ( NASDAQ:VERU ), then you'll have to look at the makeup of its share...

Yahoo | September 21, 2021

Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin (VERU-111) in 80 men with metastatic castration resistant prostate cancer who have progressed on at least one novel androgen receptor targeting agent were presented at the European Society for Medical Oncology (ESMO) Congress 2021 being held September 16-21, 2021. Sabizabulin is a new oral chemical entity that represents a novel class of agents that target unique binding sites on microtubules to disrupt both the cytoskeleton and androgen receptor transport.

Intrado Digital Media | September 20, 2021

Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress

MIAMI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the Phase 1b/2 study of sabizabulin (VERU-111) in 80 men with metastatic castration resistant prostate cancer who have progressed on at least one novel androgen receptor targeting agent has been accepted for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 to be held September 16-21, 2021. Sabizabulin is a new oral chemical entity that represents a novel class of agents that target unique binding sites of microtubules to disrupt both the cytoskeleton and androgen receptor transport.

Intrado Digital Media | September 9, 2021

Read More 'VERU' Stories Here

VERU Price Returns

1-mo -8.69%
3-mo 17.76%
6-mo -8.48%
1-year 242.80%
3-year 517.56%
5-year 751.58%
YTD -6.47%
2020 158.21%
2019 139.29%
2018 22.81%
2017 25.27%
2016 -37.24%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9558 seconds.